# Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML

> **NCT04002115** · PHASE2 · TERMINATED · sponsor: **Milton S. Hershey Medical Center** · enrollment: 2 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Fludarabine
- **DRUG:** Busulfan
- **PROCEDURE:** Total Body Irradiation (TBI)
- **DRUG:** Cyclophosphamide
- **DRUG:** Granulocyte Colony-Stimulating Factor
- **DRUG:** Tacrolimus
- **DRUG:** Cellcept

## Key facts

- **NCT ID:** NCT04002115
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-03
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-11-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** terminated due to low accrual
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04002115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04002115, "Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04002115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*